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One sentence summary:  27 
GLP-1R agonists show promise as a therapeutic agent to lower intracranial pressure in rodents. 28 
 29 
Abstract 30 
Current therapies for reducing raised intracranial pressure (ICP) under conditions such as 31 
idiopathic intracranial hypertension or hydrocephalus have limited efficacy and tolerability. 32 
Thus, there is a pressing need to identify alternative drugs. Glucagon-like peptide-1 receptor 33 
(GLP-1R) agonists are used to treat diabetes and promote weight loss but have also been shown 34 
to affect fluid homeostasis in the kidney. Here, we investigated whether exendin-4, a GLP-1R 35 
agonist, is able to modulate cerebrospinal fluid (CSF) secretion at the choroid plexus and 36 
subsequently reduce ICP in rats. We used tissue sections and cell cultures to demonstrate 37 
expression of GLP-1R in the choroid plexus and its activation by exendin-4, an effect blocked 38 
by the GLP-1R antagonist exendin 9-39. Acute treatment with exendin-4 reduced Na
+ 
K
+ 39 
ATPase activity, a key regulator of CSF secretion, in cell cultures. Finally, we demonstrated 40 
that administration of exendin-4 to female rats with raised ICP (hydrocephalic) resulted in a 41 
GLP-1R-mediated reduction in ICP. These findings suggest that GLP-1R agonists can reduce 42 
ICP in rodents. Repurposing existing GLP-1R agonist drugs may be a useful therapeutic 43 
strategy for treating raised ICP.  44 
 45 
 46 
 47 
 48 
Introduction 49 
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Elevated intracranial pressure (ICP) is caused by alterations in the volume of either cerebral 50 
blood, cerebrospinal fluid (CSF) or brain tissue. CSF volume is tightly regulated and depends 51 
on the balance between CSF secretion, which is modulated  predominantly by the choroid 52 
plexus, and drainage through the arachnoid granulations and lymphatic (1). Reducing CSF 53 
volume, by either CSF drainage or decreasing CSF secretion is used therapeutically to lower 54 
ICP (2, 3) in conditions characterized by raised ICP such as idiopathic intracranial 55 
hypertension and hydrocephalus. 56 
In the choroid plexus, CSF is secreted by the choroid plexus epithelial (CPe) cells, and 57 
is driven by net movement of sodium ions (Na
+
) from the blood into the cerebral ventricles. 58 
This creates an osmotic gradient, which drives water transport into the cerebral ventricles. 59 
There are numerous ion channels involved in this process, but the apical Na
+
 K
+
 ATPase that 60 
pumps Na
+
 into the ventricles is the most important of these channels and represents the rate 61 
limiting step (4, 5). Specific inhibition of the Na
+
 K
+
 ATPase with ouabain, reduces CSF 62 
secretion by 70-80% (6). As such, the CPe cells function akin to inverted renal proximal tubule 63 
epithelial cells with an analogous mechanism of fluid transport (7, 8). 64 
The incretin glucagon-like peptide-1 (GLP-1), is a gut peptide secreted by the distal 65 
small intestine in response to food intake (9). GLP-1 stimulates glucose-dependent insulin 66 
secretion and inhibits glucagon release, lowering blood glucose (10). In addition, GLP-1 is 67 
synthesized in neurons of the nucleus tractus solitarius, which project to the hypothalamus (11) 68 
and promote satiety and weight loss (12-14). GLP-1 signals through the GLP-1 receptor (GLP-69 
1R), a class-B G protein-coupled receptor expressed in selected cell types within the central 70 
nervous system including the hypothalamus, hippocampus, olfactory cortex, circumventricular 71 
organs, hindbrain and choroid plexus (15-17).  72 
GLP-1 also has effects on renal proximal tubule Na
+
 secretion, reducing Na
+
 73 
reabsorption and increasing diuresis (18). Here, GLP-1R activation stimulates the conversion 74 
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of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) by adenylate 75 
cyclase. cAMP activates protein kinase A (PKA), which inhibits the Na
+
 H
+
 exchanger, thereby 76 
preventing Na
+
 reabsorption into the bloodstream (18). The diuretic actions of incretins have 77 
led to investigation of their use as antihypertensive agents (19). Similar to its activity in the 78 
kidney, we hypothesize that GLP-1 also modulates Na
+
 transport and subsequently fluid 79 
movement at the choroid plexus. We propose that GLP-1R activation may inhibit the basal Na
+ 
80 
H
+
 exchanger through cAMP-dependent PKA activation, thus impeding the Na
+
 K
+
 ATPase-81 
dependent secretion of CSF. Stabilized GLP-1 mimetics are widely used to treat diabetes and 82 
obesity, and therefore could be repurposed for treating raised ICP.  83 
In the present study, we used tissue sections and CPe cell cultures to assess the 84 
localization and distribution of the GLP-1R in rat and human choroid plexus and determined 85 
the effects of GLP-1R stimulation on CSF secretion. Furthermore, we conducted in vivo 86 
studies to evaluate the effects of GLP-1R agonists on ICP in a hydrocephalus rat model with 87 
raised ICP.  88 
 89 
Results 90 
 91 
GLP-1R expression in human choroid plexus tissue 92 
Immunohistochemical analysis using haematoxylin and eosin staining confirmed that human 93 
donor tissue comprised the choroid plexus, demonstrating choroid plexus morphology 94 
including a cuboidal CPe cell monolayer resting on a basement membrane, the underlying 95 
interstitial tissue and capillary vessels (Fig. 1A). GLP-1R mRNA expression in five human 96 
choroid plexus samples was compared to known commercially available GLP-1R-positive 97 
tissues (pooled samples; see methods for source details). Human pancreas had the highest 98 
expression of GLP-1R mRNA, with heart and ovary having the least. Human choroid plexus 99 
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showed GLP-1R mRNA expression (Fig. 1B). To determine the localization of the receptor 100 
protein, paraffin embedded human choroid plexus sections were immunostained with a specific 101 
monoclonal antibody to human GLP-1R previously validated in human and monkey tissue (20, 102 
21). Based on the morphology of the choroid plexus, GLP-1R positive staining was detected in 103 
CPe cells (Fig. 1C-F). Together, these studies demonstrate that the human choroid plexus 104 
expresses GLP-1R mRNA and protein. 105 
 106 
Exendin-4 treatment of whole rat choroid plexus in vitro 107 
Given the lack of validated antibodies against rodent GLP-1R, we instead incubated whole rat 108 
choroid plexus in vitro with a fluorescently tagged GLP-1R agonist, exendin-4 (FLEX), to 109 
demonstrate the presence of the receptor in the choroid plexus. After 15 minutes of 1µM FLEX 110 
incubation, only a few CPe cells were positive for FLEX within the cytoplasm (Fig. 2A). 111 
However this increased by 30 minutes (Fig. 2A). In both cases, GLP-1R appeared to localize 112 
predominantly in the cytoplasm, consistent with agonist-induced receptor internalization and 113 
trafficking, most likely via endosomes (22). The GLP-1R antagonist exendin 9-39 (1µM) 114 
reduced the number of FLEX-positive cells within the choroid plexus (Fig. 2A), suggesting 115 
specific binding of the FLEX ligand to GLP-1R.  116 
Next, we determined Glp-1r mRNA expression in whole rat choroid plexus tissue after 117 
incubation with 100nM exendin-4. Incubation of the rat choroid plexus with exendin-4 for 3 118 
hours showed an increase in Glp-1r mRNA compared to artificial CSF (3.21 ± 0.70 fold, 119 
P<0.01), with a return to baseline at  6 hours (0.78 ± 0.12 fold) (Fig 2B). There was also a 120 
small but detectable increase in Na
+
 K
+
 atpase mRNA expression after 3 hours of exendin-4 121 
treatment compared to incubation with artificial aCSF (1.82 ± 0.28 fold; P<0.05), which again 122 
returned to baseline at 6 hours (0.97 ± 0.21 fold) (Fig. 2C). The expression of other channels 123 
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and transporters involved in CSF secretion, including the water channel aquaporin 1 (Aqp1) 124 
and the Na
+
 H
+
 exchanger (Nhe1), were not altered after exendin-4 treatment (Fig. 2D, E). 125 
 126 
Exendin-4 treatment increases cAMP and reduces Na
+
 K
+
 ATPase activity 127 
To explore further the effects of exendin-4 on the choroid plexus, monolayers of rat CPe cells 128 
were grown in culture. These CPe cells were characterized using antibodies against specific 129 
identity markers and were shown to be similar to their in vivo counterparts (Fig. S1A), 130 
including the expression of Glp-1r mRNA (Fig. S1B). To determine the effect of exendin-4 on 131 
GLP-1R signaling, cAMP generation was assessed using two enzyme immunoassay systems. 132 
Treatment of CPe cells with exendin-4 increased cAMP compared to control (2.14 ± 0.61 fold, 133 
P<0.01) (Fig. 3A) in a concentration-dependent manner, and this could be inhibited by exendin 134 
9-39 (Fig. 3B). Forskolin, an adenylate cyclase activator, was used as a positive control to 135 
maximally stimulate cAMP production (Fig 3A-B) (5.30 ± 0.74 fold compared to control). 136 
The role of GLP-1R signaling in CSF secretion was assessed in rat CPe cell cultures by 137 
measuring Na
+
 K
+
 ATPase activity (proposed as a marker of CSF secretion from the choroid 138 
plexus) (6). Exendin-4 treatment reduced Na
+
 K
+
 ATPase specific phosphate production 139 
compared to control (39.3 ± 9.4%, P<0.05) (Fig. 3C). In addition, inhibition of PKA with PKI-140 
16-22-amide (PKI) abolished the exendin-4-induced reduction in Na
+
 K
+
 ATPase activity (95.4 141 
± 17.6%, P<0.05) (Fig. 3C).  142 
 143 
Exendin-4 treatment reduces ICP in conscious rats 144 
To establish whether exendin-4 was able to modulate ICP in vivo, healthy female adult rats 145 
were implanted with an ICP monitor (Day 0) before receiving daily subcutaneous (SC) 146 
injections of either saline or 20 µg/kg exendin-4 for 5 days (day 2-6). ICP was measured before 147 
and after the SC injection on days 2, 4 and 6 (Fig. 4A). Examples of the ICP traces are shown 148 
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in Fig. 4B. On the first day of treatment (day 2), exendin-4 significantly reduced ICP 10 149 
minutes after the SC injection; by 30 minutes ICP was 65.2 ± 6.6% of baseline compared to 150 
91.0 ± 3.9% of baseline in saline-treated rats (P<0.01) (Fig. 4C). A similar drop in ICP was 151 
observed on day 4 (50.4 ± 6.9% of baseline; P<0.001) and day 6 (54.5 ± 8.2% of baseline; 152 
P<0.001), 30 minutes after exendin-4 administration (Fig. 4D-E). 153 
In addition to reducing ICP immediately after treatment, exendin-4 had a cumulative 154 
effect on reducing ICP. Exendin-4 caused a significant reduction in ICP measured pre-dose on 155 
day 2 (baseline, 100%) to day 4 (79.3 ± 7.3%; P<0.05) and day 6 (72.5 ± 5.6%; P<0.01) (Fig. 156 
4F), which was not observed in saline-treated rats (day 2, baseline 100%; day 4, 95.5 ± 13.6%; 157 
day 6, 105.3 ± 12.5%; Fig. 4G).  158 
As there is evidence that weight loss can alter ICP (23), weights were monitored over 159 
the treatment period. Whilst both saline- and exendin-4-treated rats lost weight during 160 
treatment (P<0.05), there was no significant difference between the groups at any time point 161 
(Fig. 4H). In the saline group, weight change correlated with alterations in ICP (r=0.710, 162 
P=0.032), although no relationship was detected for the exendin-4 treatment group (r=-0.300, 163 
P=0.552) (Fig. 4I).  164 
The effect of SC administration of 20 µg/kg exendin-4 on blood and CSF pH and CSF 165 
electrolytes was analyzed 60 minutes post-treatment. Exendin-4 maintained normal blood pH 166 
(7.35 ± 0.01; Fig. 4J), however, it caused a reduction in CSF pH (7.41 ± 0.03; P<0.05) 167 
compared to saline (blood pH 7.35 ± 0.03, CSF pH 7.61 ± 0.07) (Fig. 4K). CSF Na
+
 168 
concentration remained unaltered (saline, 150.3 ± 0.9; exendin-4, 150.3 ± 0.6) (Fig. 4L), 169 
whereas the concentration of Cl
- 
ions in the CSF was reduced in the exendin-4 group (117 ± 0.5 170 
mmol/L; P<0.05) compared to the saline group (123.8 ± 0.9 mmol/L) (Fig. 4M). Exendin-4 171 
treatment also increased the concentration of Ca
2+
 ions in the CSF (1.09 ± 0.01, P>0.05) 172 
compared to saline (1.03 ± 0.02) (Fig. 4N). 173 
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 174 
Exendin-4 acts via GLP-1R in the brain to reduce ICP in rats 175 
To assess whether the reduction in ICP was specific to the brain, exendin-4 was injected into 176 
the lateral ventricle through an intracerebroventricular (ICV) cannula in anesthetized rats. ICV 177 
delivery of exendin-4 reduced ICP over time, which was significantly different from baseline at 178 
15 minutes (68.9 ± 6.4%, P<0.05). ICV delivery of saline also reduced ICP over time 179 
(technical effect due to the ICV cannula itself reducing ICP), and this was significantly 180 
different from baseline at 50 minutes (74.5 ± 7.9%, P<0.05). Over the 60 minutes of ICP 181 
measurement, ICV delivery of exendin-4 significantly reduced the area-under-the-curve (AUC) 182 
of ICP compared to saline delivered via the same route (3852 ± 397 versus 4974 ± 262 AUC, 183 
P<0.05) (Fig. 4O). To determine if the effects of exendin-4 on ICP were mediated by the GLP-184 
1R, the antagonist exendin 9-39 was continuously infused (4 µg/hour) into the lateral ventricle 185 
for 2 days prior to SC administration of either saline or 20 µg/kg exendin-4. SC injection of 186 
exendin-4 (ICV saline + SC exendin-4) lowered ICP (P<0.0001) compared to a SC injection of 187 
saline with ICV delivery of exendin 9-39 (ICV exendin 9-39 + SC saline; Fig. 4P). Central 188 
ICV exendin 9-39 infusion decreased the ICP-lowering effect of SC exendin-4 at 5 minutes 189 
(ICV exendin 9-39 + SC exendin-4 96.7 ± 13.7% vs ICV saline + SC exendin-4 65.7 ± 8.3%, 190 
P<0.001)  (Fig. 4P). These data suggest that exendin-4 in part exerts its effects on ICP via the 191 
GLP-1R signaling pathway in the brain.  192 
 193 
Exendin-4 reduces ICP in a dose-dependent manner and the effects last for 24 hours 194 
Rats were treated subcutaneously with 1, 3 and 5 µg/kg exendin-4 to determine whether 195 
exendin-4 reduces ICP at lower concentrations. At 60 minutes 1, 3 and 5 µg/kg exendin-4 196 
significantly reduced ICP to 79.0 ± 7.0% of baseline (P<0.05), 69.9 ± 8.8% of baseline 197 
(P<0.0001) and 60.6 ± 3.6% of baseline (P<0.0001), respectively, compared to saline (97.2 ± 198 
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2.5% of baseline) (Fig. 5A-B). Five µg/kg exendin-4 showed the greatest reduction in ICP and 199 
the effect was still present 3 hours after the treatment (P<0.001). Conversely, in 1 and 3µg/kg 200 
exendin-4 groups ICP had returned to baseline by 3 hours (Fig. 5C). 201 
Alterations in mRNA and protein expression of GLP-1R and molecules involved in CSF 202 
secretion were assessed in the choroid plexus of rats 3 hours after treatment with 1, 3 and 5 203 
µg/kg exendin-4. Glp-1R and Na
+
 K
+
 atpase mRNA expression was not altered by exendin-4 204 
treatment (Fig. 5D-E). Conversely, there was a 2-fold increase in the amount of Aqp1 mRNA 205 
in the 5 µg/kg exendin-4 treatment group (P<0.05) (Fig. 5F), and a 4-fold increase in the 206 
amount of Nhe1 mRNA expression in the 1 µg/kg exendin-4 treatment group (P<0.05) (Fig. 207 
5G). Although no significant changes were observed in Na
+
 K
+
 atpase mRNA expression, 208 
there was a small increase in Na
+
 K
+
 ATPase protein in the 5 µg/kg exendin-4 treatment group 209 
(2.16 ± 0.22 AU, P<0.05) (Fig 5H-I). Two bands were observed for the water channel 210 
aquaporin 1 (AQP1), representing the glycosylated (top band) and non-glycosylated (bottom 211 
band) forms of AQP1 (Fig. 5H). The total amount of AQP1 protein was slightly reduced by 1 212 
and 3 µg/kg exendin-4 treatment but not with the higher 5 µg/kg exendin-4 dose (1 µg/kg, 1.96 213 
± 0.17 AU, P<0.05, 3 µg/kg, 1.75 ± 0.08 AU, P<0.01, 5 µg/kg, 2.75 ± 0.30 AU) (Fig. 5J). The 214 
ratio of glycosylated AQP1 to non-glycosylated AQP1 was increased after 1 and 3 µg/kg 215 
exendin-4 treatment but not after 5 µg/kg exendin-4 treatment (1µg/kg , 0.97 ± 0.06 AU, 216 
P<0.05, 3 µg/kg, 1.08 ±0.06 AU, P<0.01, 5 µg/kg, 0.81 ± 0.08 AU) (Fig. 5K). Glycosylation is 217 
important for intracellular trafficking and protein stability, making proteins more resistant to 218 
proteolysis (24), therefore these data suggest that exendin-4 may lower AQP1 through 219 
enhanced degradation of the non-glycosylated AQP1. 220 
The effect of 5 µg/kg exendin-4 was monitored for 24 hours in healthy rats to determine its 221 
duration of action. A single SC injection of 5 µg/kg exendin-4 maintained lower ICP compared 222 
to saline over 24 hours and returned to the pre-dose ICP baseline at 24 hours (1 hour, 60.2 ± 223 
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3.5%, P<0.0001, 3 hours, 71.3 ± 3.7%, P<0.001, 6 hours, 70.3 ± 4.0%, P<0.0001, 12 hours, 224 
88.9 ± 16.6%, P<0.01, 24 hours, 100.3 ± 14.3%, P<0.01) (Fig. 6A). Effects on weight and food 225 
and water intake were also noted in relation to changes in ICP over 24 hours. Although 226 
exendin-4 caused a greater reduction in weight at 3 and 6 hours (Fig. 6B), there were no 227 
differences between food or water intake at any time point between exendin-4-treated and 228 
saline-treated rats (Fig. 6C-D). Glp-1R, Na
+
 K
+
 atpase and Nhe1 mRNA expression did not 229 
change over the 24 hour period (Fig. 6E-F,H). As shown previously, 5 µg/kg exendin-4 230 
increased Aqp1 mRNA expression at 3 hours compared to saline, although this was not 231 
observed at any other time point (Fig. 6G). There were also no significant changes in the 232 
amount of Na
+
 K
+
 ATPase or AQP1 protein over the 24 hour time period (Fig. 6I-L). 233 
 234 
Exendin-4 treatment reduces ICP in a rodent model of raised ICP  235 
To determine the efficacy of exendin-4 to reduce ICP under conditions of raised ICP, a well-236 
characterized kaolin model of hydrocephalus in rats was used. Kaolin, an aluminium silicate, 237 
acts as an irritant, inducing an inflammatory response with concomitant deposition of collagen 238 
and dense fibrosis in areas of the subarachnoid space close to the injection site, which leads to 239 
raised ICP (25, 26). Kaolin was injected into the cisterna magna, leading to development of 240 
hydrocephalus, before implantation of the ICP monitor. ICP was recorded before and after a 241 
SC injection of either saline or 20 µg/kg exendin-4 (Fig. 7A). The injection of kaolin 242 
significantly increased baseline ICP (11.1 ± 1.3 mmHg; P<0.0001) compared to that of normal 243 
rats (5.5 ± 0.4 mmHg) (Fig. 7B). Exendin-4 treatment significantly reduced ICP almost 244 
immediately after the SC injection, and at 30 minutes was 62.6 ± 5.1% of baseline (P<0.0001) 245 
compared to 105.0 ± 4.6% of baseline in saline-treated rats (Fig. 7C). Eight rats in the kaolin 246 
group had baseline ICP values of greater than 10 mmHg and had an average baseline ICP of 247 
13.7 ± 0.7mmHg. In these rats (ICP >10mmHg), the ICP values at 30 minutes were 56.6 ± 248 
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5.7% of baseline (n=4) in the exendin-4 treatment group compared to 106.7 ± 8.6% of baseline 249 
(n=4) in the saline treatment group (Fig. 7C). In the rodents with elevated ICP, the ICP 250 
waveform was very unstable, with the appearance of B-waves characteristic of pathologically 251 
elevated ICP and a reduction in brain compliance (27). These were abolished in rats receiving 252 
exendin-4 but not saline (Fig. 7D).  253 
 254 
Discussion 255 
The aim of the present study was to establish whether GLP-1 had a role in modulating CSF 256 
secretion and ICP. We were able to demonstrate that the GLP-1R agonist exendin-4 was able to 257 
reduce ICP in conscious healthy female rats and in a rat model of raised ICP. In addition, our 258 
results suggest that the ICP-lowering properties of exendin-4 may occur through reduced CSF 259 
secretion at the choroid plexus, implied by the reduction in Na
+
 K
+
 ATPase activity in CPe 260 
cells. Furthermore, our data suggest that exendin-4 modulates CSF production in vitro through 261 
the GLP-1R/cAMP/PKA signaling pathway. 262 
Alvarez et al. (15) first described the presence of the GLP-1R in the rat ependyma and 263 
choroid plexus by in situ hybridisation, but did not characterize the cellular localization of this 264 
receptor. Our studies corroborate these findings and demonstrate further that GLP-1R mRNA 265 
and protein are present in both rat and human choroid plexus. We localized the GLP-1R protein 266 
in tissue sections of the human choroid plexus to the CPe cells using a monoclonal antibody, 267 
and showed the presence of the receptor in the rat choroid plexus using fluorescently tagged 268 
exendin-4. We note that no specific antibody exists for mouse/rat tissue so rodent tissue was 269 
not examined for GLP-1R protein expression. In any case, our studies are in keeping with 270 
others showing localization of the GLP-1R in monkey kidney and human GLP-1R transfected 271 
cells (20, 21). G-protein coupled receptors undergo internalization, trafficking and 272 
recycling/degradation following agonist stimulation (28). We speculate that such dynamics 273 
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may allow the GLP-1R to be stimulated from both sides of the choroid plexus (Fig. S2A). 274 
Although GLP-1R mRNA and protein expression were in general low, it has recently been 275 
shown that activation of the receptor requires femto- to picomolar concentrations of GLP-1R, 276 
so even faced with low abundance, signaling would be expected in the presence of exendin-4 277 
(29).  278 
We successfully cultured monolayers of rat CPe cells, which we used as an in vitro cell 279 
culture model of the rat choroid plexus to assess CSF secretion. The Na
+
 K
+
 ATPase is 280 
localized to the apical surface and is the driving force for transporting Na
+
 ions from the 281 
choroid plexus into the CSF against its concentration gradient. Many studies have 282 
demonstrated that modulation of Na
+
 K
+
 ATPase expression or activity directly correlates with 283 
CSF secretion (6, 30-33). We were able to show that exendin-4 reduces Na
+
 K
+
 ATPase 284 
activity, suggesting reduced CSF secretion at the choroid plexus. Previous studies have shown 285 
similar effects of exendin-4 on Na
+
 K
+
 ATPase activity in the renal system (34). In kidney 286 
proximal tubule epithelial cells and pancreatic beta cells, GLP-1 modulates Na
+
 concentration 287 
through increased cAMP and PKA activation (18, 35). Using two different techniques, 288 
exendin-4 was seen to induce a concentration-dependent rise in cAMP in the choroid plexus, 289 
which was inhibited by the GLP-1R antagonist, exendin 9-39. Furthermore, a PKA inhibitor 290 
blocked the effects of exendin-4 on Na
+
 K
+
 ATPase activity, although we acknowledge that 291 
such approaches can be non-specific and further studies using specific knockout animals are 292 
required. Altogether, these data indicate that the cAMP/PKA-dependent pathway may be 293 
involved in the GLP-1R-mediated reduction in CSF secretion at the choroid plexus. In the 294 
kidney, GLP-1R agonist treatment increases diuresis through phosphorylation of the Na
+
 H
+
 295 
exchanger (18, 36). There are PKA phosphorylation sites present on both the Na
+
 H
+
 exchanger 296 
and the Na
+
 K
+
 ATPase (37), therefore, in the choroid plexus, phosphorylation of either the Na
+
 297 
H
+
 exchanger or the Na
+
 K
+
 ATPase may result in inhibition of Na
+
 transport across the cells 298 
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and thus CSF production (Fig. S2B-C). In the choroid plexus, the Na
+
 K
+
 ATPase can also be 299 
phosphorylated by PKC (37). Interestingly, GLP-1R is able to signal through the PKC pathway 300 
in pancreatic beta cells (29, 38, 39). Therefore, the GLP-1R/PKC signaling pathway may also 301 
have a role in reducing CSF secretion and warrants further investigation. 302 
The key finding of this study is that subcutaneous exendin-4 treatment is able to reduce 303 
ICP in vivo in normal rats and rats with raised ICP. In addition, the effect on ICP of a single 304 
administration of exendin-4 lasted for 24 hours and cumulative dosing reduced the pre-dose 305 
ICP. This suggests that exendin-4 may be able to maintain low ICP over a long period. This is 306 
an important advance, as there are very limited specific therapeutic options to clinically reduce 307 
and maintain low ICP under conditions of raised ICP. The main therapeutic agent for managing 308 
chronic raised ICP is acetazolamide, a carbonic anhydrase inhibitor. However, in idiopathic 309 
intracranial hypertension, acetazolamide is associated with limited efficacy and poor 310 
tolerability (48% withdrawal) (2), and is contraindicated for use in premature infants with post-311 
haemorrhagic hydrocephalus (40). On the other hand, treatment with incretin mimetics is 312 
generally well tolerated, with the main side effects being transient nausea, constipation and 313 
diarrhea, and these drugs do not induce hypoglycemia (41). In patients taking the GLP-1R 314 
agonist liraglutide, drug withdrawal due to side effects was only 5.4% in the cohort receiving 315 
the highest dose (3mg; 12).  316 
There are, however, a number of limitations to the present study. To determine the 317 
central actions of exendin-4 on ICP, we had to deliver exendin-4 directly into the brain’s 318 
ventricular system. The injection itself may have a direct effect on ICP and could mask any 319 
changes in ICP relating to the treatment. To try to minimize these effects, we implanted an ICV 320 
cannula 2 days prior to the injection. Nonetheless, as it was not possible to completely seal the 321 
system, ICP showed a slight decrease in saline-treated rats. However, we were still able to 322 
establish a significant reduction in ICP with exendin-4 treatment. The study design was also 323 
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limited by the lack of blinding during the intervention, although the data were analyzed by 324 
different individuals with the same outcome. ICP was monitored continuously via automated 325 
software thus removing measurement bias. It will be of interest to study in the future, 326 
prolonged dosing in a rat model of hydrocephalus. However, this will require considerable 327 
technical optimization, given that ICP is notoriously difficult to measure in such models where 328 
recordings are typically only accurate immediately before euthanasia (42, 43). 329 
GLP-1R agonists also have peripheral actions that have the potential to indirectly affect 330 
ICP. Whilst incretin mimetics have been shown to acutely increase heart rate and blood 331 
pressure (44), hypertension would be expected to cause the opposite effect to that seen here due 332 
to increased choroid plexus permeability and fluid secretion (45, 46). Indeed, our data imply 333 
that the effect of exendin-4 on ICP dynamics is through central mechanisms, since ICV 334 
infusion of exendin 9-39 partially inhibited  the action of SC exendin-4. Exendin 9-39 may not 335 
have fully inhibited the actions of exendin-4, since the inhibitor was infused into the ventricle 336 
rather than being given as a bolus injection. However, it is also possible that the effects of 337 
exendin-4 are not fully mediated by GLP-1R and this requires further investigation. Previous 338 
studies have also demonstrated only moderate effects on attenuating exendin-4 induced food 339 
intake suppression at early time points following ICV bolus of exendin 9-39 (47). Nevertheless, 340 
the central actions of exendin-4 are further supported by the fact that exendin-4 lowered CSF 341 
pH whereas blood pH remained unchanged, which is supported by other studies showing that 342 
GLP-1 does not affect blood pH (19). It remains unclear how the subcutaneous administration 343 
of the GLP-1R agonist exendin-4 exerts its central effects on the choroid plexus. Following 344 
subcutaneous administration, circulating exendin-4 may cross the fenestrated capillaries in the 345 
choroid plexus and stimulate the GLP-1R on the basolateral side of the CPe cells. Otherwise, it 346 
is possible that exendin-4 crossed the blood brain barrier (48, 49) or entered the CSF via the 347 
circumventricular organs, where it is able to stimulate the receptors on the apical surface of the 348 
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CPe cells. Indeed, liraglutide readily crosses into the hypothalamic arcuate nucleus (50), and in 349 
vivo imaging studies in rodents using fluorescently-tagged ghrelin show passage of the gut 350 
peptide to the same region via fenestrated capillaries of the median eminence (51). Lastly, 351 
exendin-4 may stimulate vagal afferents that project to the nucleus tractus solitarius (11). This 352 
may lead to secretion of GLP-1 through a widespread network of fibres projecting to the third 353 
ventricle allowing GLP-1 to enter the CSF (Fig. S2A). 354 
In summary, exendin-4 reduces Na
+
 K
+
 ATPase activity at the choroid plexus, implying 355 
a reduction in CSF secretion, and lowers ICP in conscious rats with and without elevated ICP. 356 
This work demonstrates that GLP-1R agonists may provide an alternative treatment for raised 357 
ICP in conditions such as idiopathic intracranial hypertension and hydrocephalus, and warrants 358 
further clinical investigation in humans. 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
 371 
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 375 
Materials and Methods 376 
 377 
Study design 378 
The main aim of this study was to explore the potential of exendin-4, a GLP-1R agonist, to 379 
modulate CSF secretion and subsequently reduce ICP. Three experimental studies were 380 
performed: (i) in vitro analysis of the GLP-1R and downstream signaling pathway in human  381 
and rat choroid plexus, GLP-1R expression was determined through mRNA analysis, 382 
immunostaining of human choroid plexus tissue sections and fluorescently tagged exendin-4 383 
binding to rat choroid plexus explants. The downsteam signaling pathway was assessed in rat 384 
CPe cell culture by measuring cAMP generation and Na
+
 K
+
 ATPase activity. In vivo studies to 385 
determine the efficacy of exendin-4 to reduce ICP were conducted in (ii) healthy rats and (iii) 386 
in a pathological model of raised ICP, a rat model of hydrocephalus. The sample size (n=4-9 387 
per experimental group) for the in vivo studies was based on the resources equation as the 388 
effects size was unknown. Exact numbers for each experiment are included below and in the 389 
figure legends. The investigators were not blinded when conducting or evaluating the 390 
experiments and the rats were randomly assigned to the treatment and control groups. 391 
 392 
Human tissue 393 
Human choroid plexus samples were obtained from the Parkinson's UK Brain Bank at Imperial 394 
College London, under the ethical approval of the Wales Research Ethics Committee (Ref. No. 395 
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08/MRE09/31+5). Informed consent was obtained for the use of post mortem tissue for 396 
research. Samples were stored in RNALater at -80⁰C before being processed for qPCR 397 
following the protocol stated in the supplementary methods. Pooled human pancreas (540023), 398 
heart (540011) and ovary (540071) RNA was purchased from Agilent Technologies. Fresh 399 
choroid plexus samples were fixed in 4% formaldehyde before embedding in paraffin wax.  400 
 401 
Experimental animals 402 
For the in vitro work, 150-200g female Sprague-Dawley rats (Charles River) were used at the 403 
University of Birmingham in accordance with the Animals and Scientific Procedures Act 1986, 404 
licensed by the UK Home Office and approved by the University of Birmingham Ethics 405 
Committee. For the in vivo studies, which were conducted in Rigshospitalet-Glostrup, 150-406 
250g female Sprague-Dawley rats (Taconic) were housed in groups of 4, kept under a 12 hour 407 
light/dark cycle with free access to food and water. All experimental procedures were approved 408 
by the Danish Animal Experiments Inspectorate (license number 2014-15-0201-00256 and 409 
2012-15-2934-00283). After treatments and surgical procedures, the rats were monitored daily 410 
for any adverse effects. Female rats were used to ensure the results were relevant to conditions 411 
such as idiopathic intracranial hypertension. 412 
 413 
Daily subcutaneous injection of exendin-4 in normal conscious rats. On day 0, the epidural 414 
ICP probe was implanted and the animal allowed to recover. On day 2, 4 and 6, for the ICP 415 
recordings the rats were sedated with midazolam (2.5 mg/kg subcutaneous injection) in an 416 
infusion cage (Instech Laboratories), which had a swirl lever arm to ensure unhindered 417 
movement. A stable baseline ICP reading was recorded for around 30 minutes before the rats 418 
received a SC injection of either saline (n=9) or 20µg/kg exendin-4 (n=9). ICP was recorded 419 
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for a further 60 minutes after which the rat was returned to its normal cage. The daily SC 420 
injections of saline or exendin-4 were performed at similar times of the day for each rat. 421 
 422 
ICV injection of exendin-4 in anesthetized rats. To determine whether the effects of 423 
exendin-4 on ICP were due to central activity the rats were fitted with an ICV cannula at the 424 
same time as the epidural ICP probe implantation and the rat allowed to recover. Subsequent 425 
ICP recordings during exendin-4 treatment were done under anaesthesia. A stable baseline ICP 426 
reading was recorded for around 30 minutes before the following treatments were then 427 
administered ICV in a counterbalance design: (1) 1µl saline (n=8) and (2) 0.3µg/1µl exendin-4 428 
(n=6). ICP was recorded for a further 60 minutes after which the rat was allowed to recover. 429 
Injection treatments were separated by 2-3 days. 430 
 431 
Continuous ICV infusion of exendin 9-39 with SC injection of exendin-4 in conscious rats. 432 
To determine whether the effects of exendin-4 on ICP are through the GLP-1R, rats were fitted 433 
with an osmotic pump attached to an ICV cannula containing either saline or exendin 9-39 at 434 
the same time as the epidural ICP probe implantation. On day 2 the rats were sedated, a stable 435 
baseline recorded before a SC injection of either saline or 20µg/kg exendin-4. ICP was then 436 
recorded for a further 60 minutes. The rats were therefore assigned to 3 treatment groups: (1) 437 
Saline filled osmotic pump with SC injection of exendin-4 (ICV saline + SC exendin-4; n=6); 438 
(2) exendin 9-39 filled osmotic pump with SC injection of saline (ICV exendin 9-39 + SC 439 
saline; n=5); and (3), exendin 9-39 filled osmotic pump with SC injection of exendin-4 (ICV 440 
exendin 9-39 + SC exendin-4; n=6).  441 
 442 
Exendin-4 dose response and time course experiment. Rats underwent the same procedure 443 
as outlined in experiment 1. For the dosing experiment the rats were given either 1 (n=6), 3 444 
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(n=6) or 5µg/kg exendin-4 (n=6) and ICP recorded for 3 hours. For the time course experiment 445 
rats were given either saline (n=18 for ICP data but only 4 were used for choroid plexus 446 
analysis) and ICP recorded for 24 hours, or 5µg/kg exendin-4 and the ICP recorded for 6 (n=6), 447 
12 (n=6) and 24 hours (n=12 for ICP data but only 6 were used for choroid plexus analysis). 448 
After each time point the rats were killed with an overdose of euthatol and transcardially 449 
perfused with ice cold PBS. The choroid plexus was then dissected, frozen immediately and 450 
stored at -80ºC for qPCR and western blot analysis (described in detail in the supplementary 451 
methods). 452 
 453 
SC injection of exendin-4 in conscious hydrocephalic rats. We used the kaolin model of 454 
hydrocephalus as our model of raised ICP. On day 0 the rats received an injection of kaolin to 455 
induce hydrocephalus and the rat allowed to recover. On day 6-8 the rats were fitted with an 456 
epidural ICP probe and the rat was then allowed to recover in the infusion cages still connected 457 
to the transducer so that the ICP could be continuously measured overnight to establish raised 458 
ICP. The following morning, after establishing the baseline ICP reading was stable, the rats 459 
received a SC injection of either saline (n=6, n=4 >10mmHg) or 20µg/kg exendin-4 (n=6; n=4 460 
>10mmHg). ICP was then recorded for a further 60 minutes. 461 
 462 
Statistical analysis 463 
Values are represented as mean and standard error of the mean (SEM). The majority of the data 464 
was analyzed using GraphPad Prism software, however, the time course experiment with 465 
5µg/kg exendin-4 was analyzed using SPSS due to missing data points. For the ELISA cAMP 466 
analysis, the non-parametric Kruskall-Wallis test was used, and was followed by Mann-467 
Whitney test (two-tailed) with the appropriate adjustment for multiple comparisons 468 
(Bonferroni). T-test or One-way ANOVA (followed by a post hoc Tukey test) was used for the 469 
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comparison of qPCR, western blot and Na
+
 K
+
 ATPase activity. Two-way ANOVA with 470 
Sidak’s multiple comparison test was used for the comparison of ICP between two groups over 471 
a period of time. Values were considered statistically significant when P values were *P<0.05, 472 
**P<0.01, ***P<0.001, ****P<0.0001. Individual level data are included in table S1. 473 
 474 
 475 
 476 
Supplementary Materials 477 
Supplementary Materials and Methods 478 
Fig. S1. Characterisation of primary rat choroid plexus epithelial cells in vivo and in vitro. 479 
Fig. S2. Suggested route for GLP-1 action at the choroid plexus 480 
Table S1. Individual level data corresponding to the different figures. 481 
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 671 
Figure legends 672 
 673 
Fig. 1. GLP-1R expression in post-mortem human choroid plexus tissue in vitro. (A) 674 
Representative image of haematoxylin and eosin staining of human choroid plexus tissue 675 
section demonstrating classic choroid plexus morphology. (B) The histogram shows GLP-1R 676 
mRNA expression in human pancreas (n=1), heart (n=1), ovary (n=1) and choroid plexus 677 
(n=5). (C-D) Representative images of GLP-1R staining of paraffin-embedded human choroid 678 
plexus counterstained with haemotoxylin. Sections were incubated without primary antibody 679 
(C) and with the human GLP-1R antibody MAb 3F52 (D). (E-F) High magnification of the 680 
boxed regions shown in C and D respectively. Scale bars, 100µm, BV – blood vessel and CPe 681 
– choroid plexus epithelial cell. 682 
 683 
Fig. 2. Expression of GLP-1R after treatment with exendin-4 in rat choroid plexus in 684 
vitro. (A) Representative images of rat choroid plexus after treatment with artificial CSF 685 
(aCSF) as control or fluorescently labelled exendin-4 (FLEX) in the presence or absence of the 686 
GLP-1R antagonist exendin 9-39. DAPI (blue) was used as a nuclear marker; scale bar, 50µm 687 
(insert, 25µm).  (B-E) The histograms represent the fold change in mRNA expression of Glp-688 
1r (B), Na
+
 K
+
 atpase (C), Aqp1 (D) and Nhe1 (E) (aCSF n=6; 3hr n=7, 6hr n=7) *P<0.05, 689 
**P<0.01; ANOVA with Tukey’s multiple comparisons test. 690 
 691 
Fig. 3. Effect of exendin-4 treatment on cAMP and Na
+
 K
+
 ATPase activity in CPe cells. 692 
(A-B) The histograms represent the amount of cAMP generated after incubation with control, 693 
exendin-4 with and without 1µM exendin 9-39 and forskolin (positive control) using two 694 
different methods of cAMP detection (A - control n=8, exendin-4 n=8, Forskolin n=5, B - 695 
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control n=5, 1nM n=5, 10nM n=6 and 100nM exendin-4 n=5; with 1µM exendin 9-39 n=6, 696 
n=5 and n=5 respectively). (C)  Na
+
 K
+
 ATPase activity was measured by determining the 697 
concentration of inorganic phosphate generated by the hydrolysis of ATP that was sensitive to 698 
ouabain (Na
+
 K
+
 ATPase inhibitor) (control n=13, exendin-4 n=7; PKI n=8; exendin-4 + PKI 699 
n=8).  *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, NS no significance. (A) Kruskal-700 
Wallis followed by Mann-Whitney tests (Bonferroni correction); (B-C) ANOVA with Tukey’s 701 
multiple comparisons test. Protein kinase A inhibitor, PKI. 702 
 703 
Fig. 4. Effect of exendin-4 on ICP in healthy conscious rats. (A) Overview of the 704 
experimental design in normal rats. Rats were fitted with an epidural ICP probe and allowed to 705 
recover. Treatment was given daily for 5 days and ICP was recorded on days 2, 4 and 6, before 706 
and after the rats received a subcutaneous (SC) injection of either saline (n=9) or 20µg/kg 707 
exendin-4 (n=9). (B) Example ICP traces of saline (blue) and exendin-4 (red) treatment. Spikes 708 
in the trace represent when the animal was moving (*) and accurate recording of ICP was 709 
confirmed by the response to jugular vein compression. (C-E) Line graphs showing the 710 
percentage of baseline ICP after SC injection of either saline or exendin-4 on day 2 (C), day 4 711 
(D) and day 6 (E). (F-G) Histograms showing the pre-dose and 60 minutes post treatment ICP 712 
values (% of baseline on day 2) on days 2, 4 and 6 for exendin-4 (F) and saline (G). (H) Line 713 
graph of the % change in weight from day 2 (start of treatment) showing that both saline and 714 
exendin-4 treated rats lost weight but there was no significant difference between the groups on 715 
day 4 or 6. (I) Scatter plot of weight change (g) vs ICP change (mmHg) in the saline (blue n=4) 716 
and exendin-4 (red n=5) groups. (J-N) Histograms showing blood pH (J) and CSF pH (K), and 717 
the concentration of Na
+
 (L) Cl
-
 (M) and Ca
2+
 (N) in the CSF, 60 minutes after a SC injection 718 
of either saline or 20µg/kg exendin-4. (O) ICP was measured before and after a 1µl 719 
intracerebroventricular (ICV) injection of either saline (n=8) or 0.3µg exendin-4 (n=6). (P) 720 
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Exendin 9-39 was continually infused (4µg/µl/hr) into the lateral ventricle (ICV) and ICP was 721 
measured before and after a SC injection of either 20µg/kg exendin-4 (ICV exendin 9-39 + SC 722 
exendin-4, n=6) or saline (ICV exendin 9-39 + SC saline, n=5) and compared to continuous 723 
saline infusion (ICV Saline + SC exendin-4, n=6). *P<0.05, **P<0.01, ***P<0.001; (C-H, O-724 
P) Two way ANOVA with Sidak’s multiple comparison test; (J-N) T-test (two-tailed).  725 
 726 
Fig. 5. Effects of different doses of exendin-4 on ICP, mRNA and protein expression in 727 
healthy conscious rats. (A-B) Dose-response of exendin-4’s effects on ICP following SC 728 
administration of 1 (n=6), 3 (n=6), 5 (n=23) and 20 µg/kg (n=9) exendin-4 compared to saline 729 
(n=18) at 30 and 60 minutes. (C) Line graph showing the percentage of baseline ICP after 730 
treatment with 1, 3 or 5µg/kg exendin-4 measured over 3 hours. (D-G) The histograms show 731 
Glp-1R (D), Na
+
 K
+
 atpase (E), Aqp1 (F) and Nhe1 (G) mRNA expression in the rat choroid 732 
plexus after saline treatment (n=4) or treatment with 1 (n=5), 3 (n=6), 5 µg/kg (n=6) exendin-4. 733 
(H) Representative western blots and  (I-K) semi-quantitative protein analysis for (I) Na
+
 K
+
 734 
ATPase (112kDa) and (J) total AQP1, either non-glycosylated (NG, 29kDa) or glycosylated 735 
(G, 35kDa); β-actin (42kDa) loading control. (K) Histogram shows the ratio of G to NG AQP1. 736 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (B-C) Two-way ANOVA with Sidak’s 737 
multiple comparison test; (D-G and I-K) ANOVA with Tukey’s multiple comparison test.  738 
 739 
Fig. 6. Effects of Exendin-4 time course on ICP, mRNA and protein expression in healthy 740 
conscious rats. (A) Line graph showing the percentage of baseline ICP after a single SC 741 
injection of saline (n=18) or 5µg/kg exendin-4 (n=24) measured over 24 hours. (B-D) 742 
Histograms showing weight loss (B), water intake (C) and food intake (D) in rats treated with 743 
saline (n=4) or 5µg/kg  exendin-4 at 3 (n=6), 6 (n=6) and 24 hours (n=6). (E-H) Histograms 744 
representing Glp-1r (E), Na
+
 K
+
 atpase (F), Aqp1 (G) and Nhe1 (H) mRNA expression in the 745 
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rat choroid plexus after treatment with saline (n=4) and 5µg/kg exendin-4 at 3 (n=6), 6 (n=5) 746 
and 24 hours (n=5). (I) Representative western blots and (J-L) semi-quantitative protein 747 
analysis for (J) Na
+
 K
+
 ATPase (112kDa) and (K) total AQP1 either nonglycosylated (NG, 748 
29kDa) or glycosylated (G, 35kDa); β-actin (42kDa) loading control. (L) The histogram shows 749 
the ratio of G to NG AQP1. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; (A-D) Two-way 750 
ANOVA with Sidak’s multiple comparison test; (E-H and J-L) ANOVA with Tukey’s multiple 751 
comparison test.   752 
 753 
Fig. 7. Effect of exendin-4 on ICP in a rat model of raised ICP (hydrocephalic). (A) 754 
Overview of the experimental plan. Kaolin was injected into the cisterna magna to induce 755 
hydrocephalus. On Day 6 the ICP monitor was implanted under anaesthesia and ICP was 756 
recorded overnight to allow the ICP to normalize after implantation. On Day 7, the rats were 757 
given a SC injection of either saline (n=6) or 20µg/kg Exendin-4 (n=6), and ICP was recorded 758 
for a further 60 minutes. (B) Dot plot showing the individual baseline ICP values (mmHg) for 759 
the normal rats and rats injected with kaolin. The kaolin group had significantly higher baseline 760 
ICP values compared to the normal group, with 8/12 rats having an ICP value of >10mmHg. 761 
(C) Line graph showing the percentage of baseline ICP after treatment with either saline (dark 762 
blue, n=6) or exendin-4 (dark red, n=6). The groups could also be further divided into those 763 
with ICP >10mmHg in the saline group (light blue, n=4) and exendin-4 group (light red, n=4). 764 
(D) Example ICP trace in a hydrocephalic rat before and after treatment with exendin-4. Before 765 
treatment the rat exhibited pathological ICP B-waves (b), which were abolished following 766 
treatment with exendin-4. **** P<0.0001; (B) T-test (two tailed); (C) Two-way ANOVA with 767 
Sidak’s multiple comparison test.  768 
